Solulink Appoints Life Science Industry Veteran Jack Ball as Chief Executive Officer Mr. Ball brings a long history of strategic leadership and in-depth knowledge of the life sciences and flow cytometry markets to Solulink.
SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Solulink, Inc., an emerging life science tools company with expertise in biomolecular linking, announced today that Jack Ball has been appointed as the company's Chief Executive Officer. A proven performer, Mr. Ball will lead the company as it commercializes its HybriLink™ technology.
The HybriLink technology solves the 'missing color' problem: the inability to find the needed antibody labeled with the right fluorophore (color). Often, the desired combination is not commercially available. By providing a simple way to mix and match any fluorophore with any antibody on demand, just-in-time at the point-of-use, HybriLink dramatically streamlines the development and expansion of multicolor flow panels for flow cytometry research labs. Solulink believes that HybriLink's ability to offer all antibodies in all fluorophores – including the next generation of emerging fluorophores – resolves a fundamental challenge in flow cytometry and will expand the overall flow cytometry reagents market size. The HybriLink technology also provides increased flexibility in antibody labeling to the microscopy, western blot and ELISA markets.
Mr. Ball brings a solid track record of life sciences leadership with a strong background in commercial operations, and extensive experience in the life science markets. Most recently, he served as Chief Commercial Officer at Accuri Cytometers, Inc., before its acquisition by BD Biosciences in 2011. Prior to joining Accuri, Mr. Ball was CEO of Amnis Corporation, a venture-backed, technology start-up developing high-end imaging flow cytometers. He also served as Chief Commercial Officer for Molecular Probes, Inc. (now a part of Life Technologies), the world leader in reagents for molecular biology and cell analysis. Before that, Mr. Ball was the Senior VP & General Manager of the Life Sciences Group at Orchid Biosciences, and a senior executive at Amersham Pharmacia Biotech Inc., where he rose to President, North America, and was responsible for sales, marketing, and customer support.
In addition to Solulink, Mr. Ball serves on the board of directors of 3D Biomatrix, IntelliCyt, RealBio Technology, Swift Bioscience and ViroCyt as well as the non-profit organization, the Association of Commercial Professionals - Life Sciences (ACP-LS).
"We are very pleased to welcome Jack as Solulink's new CEO," said Walt Young, Solulink's Chairman of the Board. "Jack brings an impressive executive track record of success and major accomplishments in flow cytometry and the life sciences, and was directly responsible for driving growth in hundred million dollar businesses. His global P&L experience and extensive background in mergers, acquisition integration, operations and international expansion are assets that will greatly benefit the company's growth."
Mr. Ball stated, "I am extremely excited about joining Solulink as their CEO. Solulink has a long legacy for innovation and has all the components necessary to be successful in today's highly competitive and rapidly growing life science markets. I look forward to leading the organization as Solulink introduces and commercializes its powerful HybriLink technology worldwide."
Solulink, a privately-held life science tools company, develops, manufactures and markets proprietary, next generation linking technology for the development and improvement of products in the research assay and diagnostic markets. Solulink's latest innovation, the HybriLink Technology, improves the capabilities of end users, developers and suppliers to utilize the growing wide variety of detection technologies for research and diagnostic life science assays. Solulink markets their products directly and through distributors and licensing partners world-wide.
SOURCE Solulink, Inc.